ENTX Entera Bio Ltd

Price (delayed)

$1.21

Market cap

$59.56M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$48.08M

?
Relative Growth: Rel. Growth: 5
Relative Strength: Rel. Strength: 12
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 3

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due ...

Highlights
The debt has surged by 104% year-on-year but it has declined by 9% since the previous quarter
ENTX's quick ratio is down by 41% year-on-year but it is up by 12% since the previous quarter
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Entera Bio's gross profit has plunged by 100% YoY

Key stats

What are the main financial stats of ENTX

ENTX stock price

How has the Entera Bio stock price performed over time
Intraday
-0.82%
1 week
-0.82%
1 month
9.01%
1 year
-40.98%
YTD
-37.63%
QTD
9.01%

Financial performance

How have Entera Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.51M
Net income
-$12.38M
Gross margin
N/A
Net margin
N/A
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY
Entera Bio's gross profit has plunged by 100% YoY
ENTX's operating income is down by 24% year-on-year and by 8% since the previous quarter
The net income is down by 23% year-on-year and by 8% since the previous quarter

Price vs fundamentals

How does ENTX's price correlate with its fundamentals

Growth

What is Entera Bio's growth rate over time

Valuation

What is Entera Bio stock price valuation
P/E
N/A
P/B
5.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 8% since the previous quarter and by 3.8% year-on-year
The equity has declined by 45% year-on-year and by 18% since the previous quarter
ENTX's P/B is 9% above its 5-year quarterly average of 4.9 but 5% below its last 4 quarters average of 5.6
Entera Bio's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Entera Bio business performance
ENTX's return on equity is down by 25% since the previous quarter but it is up by 7% year-on-year
Entera Bio's ROA has decreased by 22% from the previous quarter but it has increased by 10% YoY

Dividends

What is ENTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ENTX.

Financial health

How did Entera Bio financials performed over time
ENTX's quick ratio is down by 41% year-on-year but it is up by 12% since the previous quarter
The current ratio has declined by 39% year-on-year but it is up by 14% since the previous quarter
The debt is 96% smaller than the equity
The debt has surged by 104% year-on-year but it has declined by 9% since the previous quarter
The equity has declined by 45% year-on-year and by 18% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.